Directly observed therapy for tuberculosis given twice weekly in the workplace in urban South Africa

被引:18
作者
Bechan, S
Connolly, C
Short, GM
Standing, E
Wilkinson, D
机构
[1] MRC, Ctr Epidemiol Res S Africa, ZA-3937 Hlabisa, South Africa
[2] Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England
[3] Hlabisa Hosp, Hlabisa, South Africa
[4] State Hlth Dept, Reg Off, Durban, South Africa
关键词
tuberculosis; Mycobacterium tuberculosis; chemotherapy; directly observed therapy; isoniazid; rifampicin; pyrazinamide; streptomycin;
D O I
10.1016/S0035-9203(97)90532-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Effective models of delivery of directly observed therapy (DOT) for tuberculosis in resource-poor settings are needed. Intermittent chemotherapy may be an important component of DOT delivered in the community as it means fewer visits to supervisors. There is no published evidence on the efficacy of twice weekly therapy given from the start of treatment without an intensive daily phase. We analysed date from 3 large cohort studies in a migrant, urban workforce in South Africa between 1975 and 1983. All patients received 4 drugs (isoniazid, rifampicin, pyrazinamide and streptomycin) twice weekly under direct observation by a nurse in the workplace. Of 444 patients, 378 (85.1%) completed treatment. Cure could be assessed in 362, and 348 (96.1%, 95% confidence interval 93.7-97.8%) were bacteriologically cured. Sputum status was assessed at 2-3 months in 343 patients and 309 (90.1%) were sputum negative. Eighteen patients relapsed (5.7%; 2.9/100 patient-years of observation). DOT can be effectively delivered to a migrant, urban workforce, and 4-drug therapy given twice weekly under direct observation is efficacious.
引用
收藏
页码:704 / 707
页数:4
相关论文
共 15 条
[1]  
Chalmers I., 1995, Systematic reviews
[2]  
Chan S. L., 1994, P141
[3]  
*CHIN TUB CONTR CO, 1996, LANCET, V343, P358
[4]   A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN [J].
COHN, DL ;
CATLIN, BJ ;
PETERSON, KL ;
JUDSON, FN ;
SBARBARO, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :407-415
[5]   TUBERCULOSIS-CONTROL IN RESOURCE-POOR COUNTRIES - ALTERNATIVE APPROACHES IN THE ERA OF HIV [J].
DECOCK, KM ;
WILKINSON, D .
LANCET, 1995, 346 (8976) :675-677
[6]   TUBERCULOSIS IN NEW-YORK-CITY - TURNING THE TIDE [J].
FRIEDEN, TR ;
FUJIWARA, PI ;
WASHKO, RM ;
HAMBURG, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (04) :229-233
[7]  
Harries AD., 1996, TB / HIV-A clinical manual
[8]   EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS [J].
HOPEWELL, P ;
CYNAMON, M ;
STARKE, J ;
ISEMAN, M ;
OBRIEN, R .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S282-S295
[9]   COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN 3 SUB-SAHARAN AFRICAN COUNTRIES [J].
MURRAY, CJL ;
DEJONGHE, E ;
CHUM, HJ ;
NYANGULU, DS ;
SALOMAO, A ;
STYBLO, K .
LANCET, 1991, 338 (8778) :1305-1308
[10]   PULMONARY TUBERCULOSIS IN HIV-INFECTED PATIENTS IN ZAIRE - A CONTROLLED TRIAL OF TREATMENT FOR EITHER 6 OR 12 MONTHS [J].
PERRIENS, JH ;
STLOUIS, ME ;
MUKADI, YB ;
BROWN, C ;
PRIGNOT, J ;
POUTHIER, F ;
PORTAELS, F ;
WILLAME, JC ;
MANDALA, JK ;
KABOTO, M ;
RYDER, RW ;
ROSCIGNO, G ;
PIOT, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :779-784